Prescribing adherence of antihypertensive agents in Chronic Kidney Disease (CKD) patients and its relationship with clinical outcomes

Ahmed Ibrahim Abdeltawwab Hussein; Shairyzah Ahmad Hisham; Rosnani Hashim

doi:10.53730/ijhs.v6nS7.13060

Authors

Ahmed Ibrahim Abdeltawwab Hussein Faculty of Pharmacy, University of Cyberjaya, Persiaran Bestari, 63000 Cyberjaya, Selangor, Malaysia
Shairyzah Ahmad Hisham
shairyzah@cyberjaya.edu.my
PhD, Faculty of Pharmacy, University of Cyberjaya, Persiaran Bestari, 63000 Cyberjaya, Selangor, Malaysia, Phone number: +603 8313 7051
Rosnani Hashim Faculty of Pharmacy, University of Cyberjaya, Persiaran Bestari, 63000 Cyberjaya, Selangor, Malaysia

Keywords:

Prescribing adherence, Antihypertensive agents, CKD, Clinical outcomes

Abstract

Objectives This study was conducted to evaluate the utilisation of antihypertensive agents, assess prescribing adherence and determine the relationship between guideline adherence indicator (GAI) and clinical outcomes among hypertensive CKD patients. Methods This was a retrospective cohort study involving newly diagnosed CKD patients undergoing follow-up between January to December 2018 at a tertiary Malaysian hospital. The study subjects were screened and recruited using simple random sampling according to inclusion and exclusion criteria. Clinical data was retrieved from the online medical record (eHis system) using a pre-prepared data collection form. Results A total of 74 patients were included in this study with mean (SD) age of 66.86 (10.86) years old. The majority were male (n= 39, 52.7%) and Malay (n= 34, 45.9%). The study results showed that CCB was the drug of choice prescribed, while the most commonly prescribed combination therapy was ACEI + beta-blocker + CCB and ACEI + CCB. The overall adherence to the guideline was moderate (mean (SD) GAI score of 76.25 (17.56) %). There was a significant difference in mean GAI score between subjects with controlled and uncontrolled BP (92.86 (11.11) vs 69.23 (14.88), P <0.05).

Downloads

Download data is not yet available.

References

Liyanage T, Toyama T, Hockham C, et al. Prevalence of chronic kidney disease in Asia: a systematic review and analysis. BMJ Global Health. 2022;7: e007525.

Saminathan TA, Hooi LS, Mohd Yusoff M, et al. Prevalence of chronic kidney disease and its associated factors in Malaysia; findings from a nationwide population-based cross-sectional study. BMC Nephrol. 2020; 21, 344.

Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease - A systematic review and meta-analysis. PLoS One. 2016; 11(7):e0158765.

Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: Core Curriculum. Am J Kidney Dis 2019;74(1):120-131.

Griffin KA, Polichnowski AJ, Bidani AK. Pathophysiology of Hypertension in Chronic Kidney Disease and Dialysis. In: Singh AK, Agarwal R. Core Concepts in Hypertension in Kidney Disease. Maywood: Springer; 2016. P. 35-61.

Ministry of Health, Malaysia. Clinical practice guideline (CPG) for the management of CKD. Malaysian Health Technology Assessment Section (MaHTAS); 2018.

Schneider MP, Hilgers KF, Schmid M, Hübner S, Nadal J, Seitz D, Busch M, Haller H, Köttgen A, Kronenberg F, Baid-Agrawal S, Schlieper G, Schultheiss U, Sitter T, Sommerer C, Titze S, Meiselbach H, Wanner C, Eckardt KU; GCKD Study Investigators. Blood pressure control in chronic kidney disease: A cross-sectional analysis from the German Chronic Kidney Disease (GCKD) study. PLoS One. 2018;13(8):e0202604.

Poelzl G, Altenberger J, Pacher R, Ebner CH, Wieser M, Winter A, et al. Dose matters! Optimisation of guideline adherence is associated with lower mortality in stable patients with chronic heart failure. Int J Cardiol. 2014; 175(1):83-9.

Logan AG. Hypertension in aging patients. Expert Rev Cardiovasc Ther. 2011;9(1):113-20.

Carrero J, Hecking M, Chesnaye N, et al. Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. Nat Rev Nephrol. 2018; 14, 151–164.

Hong C Y, Chia KS, Hughes K, Ling SL. Ethnic differences among Chinese, Malay and Indian patients with type 2 diabetes mellitus in Singapore. Singapore Med J. 2004; 45(4):154-160.

Tan AKG, Dun RA, Yen ST. Ethnic Disparities in Metabolic Syndrome in Malaysia: An Analysis by Risk Factors. Metabolic Syndrome and Related Disorders. 2011; 441-451.

Saminathan TA, Hooi LS, Mohd Yusoff M. et al. Prevalence of chronic kidney disease and its associated factors in Malaysia: findings from a nationwide population-based cross-sectional study. BMC Nephrol. 2020; 21, 344.

Sarafidis PA, Georgianos PI, Zebekakis PE. Comparative epidemiology of resistant hypertension in chronic kidney disease and the general hypertensive population. Semin Nephrol. 2014;34(5):483-91.

Ku E, McCulloch CE, Vittinghoff E, Lin F, Johansen KL. Use of antihypertensive agents and association with risk of adverse outcomes in chronic kidney disease: Focus on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. J Am Heart Assoc. 2018;7(19):e009992.

Zhao HJ, Li Y, Liu SM, Sun XG, Li M, Hao Y, et al. Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis. Ren Fail. 2016;38(6):849-856.

Abdulameer SA, Sahib MN, Aziz NA, Hassan Y, Alrazzaq HAA, Ismail O. Physician adherence to hypertension treatment guidelines and drug acquisition costs of antihypertensive drugs at the cardiac clinic: A pilot study. Patient Prefer Adherence. 2012; 6:101-108.